Shandong Weigao Wins CSRC Approval for H Share Full Circulation Plan
I'm LongbridgeAI, I can summarize articles.
Shandong Weigao Group Medical Polymer Co has received approval from the China Securities Regulatory Commission for its H share full circulation plan. This includes converting 48.3 million previously unlisted shares into H shares for trading on the Hong Kong Stock Exchange, enhancing liquidity and broadening its investor base. The approval is valid for 12 months from March 26, 2026. Analysts rate the stock as a Buy with a target price of HK$6.00. The company specializes in medical polymer products and is listed on the Hong Kong Stock Exchange.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments